Sensorion, a biotech working on therapies for inner ear diseases, said today that it inked a deal with Cochlear Ltd (ASX:COH) to study combination therapies for patients with cochlear implants.
According to the deal, the companies will combine Sensorion’s SENS-401 compound with cochlear implants in preclinical studies starting next year. The drug-device therapies could be in clinical trials as early as 2019, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Sensorion, Cochlear collab to study combo therapies for patients with cochlear implants appeared first on MassDevice.